The transcript offers no verified, thesis-backed trade or price target; reported orders and positions should not be treated as investment recommendations. Avoid acting on the vague MRNA short comment or the semiconductor and AI names without independent research and a clear risk plan. The key actionable lesson is to verify order status and execution, and never trade on potentially material nonpublic information.

Apple (AAPL)

• Shkreli said he was long 1,000 shares at an average price of $344.52. He also cited a price of $345.06 and an approximately $200 daily gain.
• The transcript does not provide a broader thesis for the position.

Takeaways

• Treat the position and prices as reported during a trading-assistant demonstration; the transcript does not verify that they represent a live portfolio.
• No specific buy, sell, or price-target recommendation was given.

Oracle (ORCL)

• The trading assistant reported buying 1,000 shares at $134.12. Shkreli said the position was down $15 at that point.
• No investment rationale for Oracle was discussed.

Takeaways

• The transcript provides a reported trade, not a supporting investment thesis. It is not enough on its own to assess Oracle’s prospects.

Qualcomm (QCOM), Broadcom (AVGO), Micron (MU) and Sandisk (SNDK)

• Qualcomm was described as involving intellectual property and phone chips, with a loose comparison to Broadcom. Shkreli said he was not a Qualcomm expert.
• Broadcom, Micron, and Sandisk were suggested as semiconductor-related names to look at; no specific views on their valuations or prospects were offered.

Takeaways

• These are names for further semiconductor research, not stock recommendations from the discussion.
• The broader discussion emphasized that semiconductor trades should have a thesis and risk framework rather than being based only on chart movements.

SMH (VanEck Semiconductor ETF)

• The assistant reviewed a round trip: 366 shares were sold at $546.08 and bought back at $568.61. The exchange characterized the sequence as a bad fill.
• Shkreli called it a test, so the trade should not be assumed to reflect a live position.

Takeaways

• The example highlights execution risk: selling and repurchasing at substantially different prices can hurt results, even when the investment view has not changed.

Chevron (CVX)

• The assistant reported a short position of 1,000 shares at $219.55.
• No rationale, target, or time horizon for the short was provided.

Takeaways

• The transcript offers no basis for evaluating the short thesis. A reported trade alone is not an actionable signal.

Eli Lilly (LLY)

• The assistant placed a bid for 1,000 shares at $800. Shkreli then asked to cancel it, but the assistant repeatedly failed to cancel the working order and acknowledged that it had incorrectly said the order was canceled.
• No execution was confirmed.

Takeaways

• The main insight is operational rather than company-specific: confirm order status directly, especially after a cancellation request. The transcript contains no investment thesis for Lilly.

NVIDIA (NVDA)

• The assistant reported a 1,000-share bid at $217.35, then described the position as long 1,000 shares at $217.46, with another 1,000-share bid outstanding.
• Shkreli then claimed he had received advance information from Jensen Huang about a major announcement. He later said he was joking, but the assistant refused to place further NVIDIA orders and urged him to contact compliance.
• Despite that warning, the transcript subsequently shows an order for 5,000 shares at $217.46 being sent. The trading assistant’s actions and the prank-like exchange make the status of these trades unreliable.

Takeaways

• Do not treat these orders or prices as a verified investment call; the transcript gives no public-information-based thesis for NVIDIA.
• The exchange underscores a serious compliance principle: do not trade on potentially material, non-public information. Stop trading and escalate the issue through compliance if such information arises.

Taiwan Semiconductor Manufacturing Company (TSM)

• Shkreli claimed that the supposed NVIDIA announcement involved a deal with TSM. The assistant warned that this could be material, non-public information and instructed him to stop trading TSM.
• No TSM order or purchase is confirmed in the transcript.

Takeaways

• No investment thesis was given. The TSM discussion is primarily a compliance warning, not a trading recommendation.

Microsoft (MSFT)

• Shkreli asked the assistant to place a 10-million-share market order, which it estimated would be about $5.4 billion. The assistant noted that account buying power was unavailable and that the order would remain pending until confirmed.
• After the order was confirmed, the assistant reported an implausible modeled fill and acknowledged that it could not identify a counterparty or establish that a real order would have executed that way.

Takeaways

• This was an order-control demonstration, not a credible Microsoft investment thesis or verified trade.
• The exchange illustrates why large market orders require buying-power checks and careful execution planning; the assistant itself warned that an order of this size could create substantial execution risk.

Disney (DIS)

• The assistant reported buying 10 million shares at $1.11 after Shkreli asked for a large market order. The transcript provides no credible confirmation that this was a real-world fill.

Takeaways

• The trade appears to be part of the same trading-assistant test and should not be taken as a Disney recommendation or reliable transaction record.

Intel (INTC)

• Shkreli referred to Intel trading at $95 and proposed shorting 100 million shares with a $0.05 limit, saying he did not care if the price fell to that level.
• This was an extreme hypothetical order; no execution was reported. Elsewhere, he also asked to “get me out of this Intel thing,” without enough detail to establish a position.

Takeaways

• No Intel thesis was provided. The proposed size and price underscore the importance of realistic order sizing and a defined risk framework.

CoreWeave (CRWV), SpaceX and Nebius (NBIS)

• Shkreli said CoreWeave was down while SpaceX was not, and described the companies as “basically the same company” in the context of a possible pair trade.
• He also mentioned a possible long position in CoreWeave and Nebius, but the idea was unclear and he gave no supporting thesis.
• He cautioned that CoreWeave has multiple debt tranches that need to be analyzed carefully. SpaceX is a private company, rather than a publicly traded stock.

Takeaways

• The pair-trade discussion was tentative and internally unclear; it is not a specific recommendation.
• The debt-structure comment is a stated research consideration for CoreWeave. Any comparison across these businesses would need a clearer thesis and analysis of their differences.

Moderna (MRNA)

• Shkreli said, “I think Moderna’s a short,” but added that he did not know how to explain the situation.
• No catalyst, price target, or time horizon was given.

Takeaways

• This is the clearest bearish view in the transcript, but it is unsupported by a developed thesis. It should not be treated as an actionable short recommendation without further research.

GDIS (company identity unclear in transcript)

• Shkreli said he had followed “GDIS” for years and was glad the company’s drug had been approved.
• The transcript does not clarify the company’s identity, name the drug, or discuss its commercial prospects.

Takeaways

• The comment is positive about the reported drug approval, but there is not enough information to identify the asset confidently or assess the investment implications.

Sarepta Therapeutics (SRPT)

• Shkreli said he had not looked at Sarepta in a while.
• No current view, catalyst, or investment recommendation was provided.

Takeaways

• The mention does not amount to a positive or negative investment signal.

Genentech

• Shkreli named Genentech as his favorite pharmaceutical company of all time.
• No current investment thesis or specific security was discussed.

Takeaways

• This reflects a historical preference, not a current recommendation to invest in Genentech or any related company.

MongoDB (MDB)

• Shkreli criticized a colleague for trading MongoDB without an apparent thesis, noting that it is a software company rather than a semiconductor company.
• He described it as capable of moving like high-beta tech, but said that trading outside a sector focus should have a thesis.

Takeaways

• The discussion favors matching trades to a clear investment rationale. It also warns against confusing a company’s volatility with an investment thesis.

Bitcoin (BTC)

• Shkreli said he did not know whether he was bullish on Bitcoin.
• Numbers that follow in the transcript are unclear and do not provide a reliable price target.

Takeaways

• The sentiment was uncertain, not a directional recommendation. No price target or investment timeline was given.

Biotech and drug-development themes

• Shkreli mentioned investigational drugs and said he was not a physician and did not have specific clinical trials he particularly liked.
• He said that evidence of activity from PD-L1 bispecifics would be interesting, but did not name a company, drug, or trial.

Takeaways

• The discussion points to clinical-trial results as an area of interest, but provides no specific biotech investment opportunity.
• No timelines, trial outcomes, or company-level recommendations were supplied.